Pravastatin Actavis

Country: Նոր Զելանդիա

language: անգլերեն

source: Medsafe (Medicines Safety Authority)

active_ingredient:

Pravastatin sodium 20mg;  

MAH:

Teva Pharma (New Zealand) Limited

INN:

Pravastatin sodium 20 mg

dosage:

20 mg

pharmaceutical_form:

Tablet

composition:

Active: Pravastatin sodium 20mg   Excipient: Croscarmellose sodium Iron oxide yellow Lactose monohydrate Light magnesium oxide Magnesium stearate Microcelac 100 Povidone

prescription_type:

Prescription

manufactured_by:

Biocon Limited

therapeutic_indication:

In hypercholesterolemic patients without clinically evident coronary heart disease, Pravastatin Actavis is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. Pravastatin Actavis is indicated for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. Pravastatin Actavis is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

leaflet_short:

Package - Contents - Shelf Life: Blister pack, Alu-Alu blister pack with cardboard carton secondary packaging - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture

authorization_date:

2014-01-20